Trial Outcomes & Findings for CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19) (NCT NCT05236270)
NCT ID: NCT05236270
Last Updated: 2024-05-22
Results Overview
Investigators will measure this with the question "How likely are you to get an approved COVID-19 vaccine?" and "If you have received 1 dose of the Janssen vaccine or 2 doses of the Moderna or Pfizer vaccine, how likely are you to get an approved booster shot?" We will compare intention to receive a COVID-19 vaccine or booster among those receiving the interventions compared to those not receiving the intervention
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
312 participants
Primary outcome timeframe
Baseline to Post-Intervention Survey (approximately 15-30 minutes)
Results posted on
2024-05-22
Participant Flow
Participants were recruited from March 25, 2022 through June 27, 2023 from 21 sites across Oklahoma. Recruitment sites included community events, employee wellness events at healthcare facilities, and conferences.
After participants provided informed consent and HIPAA authorization, participants were randomized to a treatment condition.
Participant milestones
| Measure |
Condition 4
Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 1
Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
|
Condition 2
Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 3
Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
|
Condition 5
Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 6
Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an attention control educational message.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
|
Condition 7
Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
|
Condition 8
Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
35
|
42
|
42
|
35
|
42
|
31
|
41
|
44
|
|
Overall Study
COMPLETED
|
35
|
39
|
40
|
35
|
40
|
31
|
40
|
41
|
|
Overall Study
NOT COMPLETED
|
0
|
3
|
2
|
0
|
2
|
0
|
1
|
3
|
Reasons for withdrawal
| Measure |
Condition 4
Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 1
Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
|
Condition 2
Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 3
Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
|
Condition 5
Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 6
Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an attention control educational message.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
|
Condition 7
Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
|
Condition 8
Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
|---|---|---|---|---|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
0
|
3
|
2
|
0
|
2
|
0
|
1
|
3
|
Baseline Characteristics
Information on sex was missing for 8 participants across treatment groups.
Baseline characteristics by cohort
| Measure |
Condition 1
n=42 Participants
Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
|
Condition 2
n=42 Participants
Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 3
n=35 Participants
Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
|
Condition 4
n=35 Participants
Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 5
n=42 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 6
n=31 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an attention control educational message.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
|
Condition 7
n=41 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
|
Condition 8
n=44 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Total
n=312 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
43.5 years
STANDARD_DEVIATION 12.5 • n=42 Participants
|
47.0 years
STANDARD_DEVIATION 14.5 • n=42 Participants
|
52.4 years
STANDARD_DEVIATION 13.4 • n=35 Participants
|
46.8 years
STANDARD_DEVIATION 14.3 • n=35 Participants
|
44.7 years
STANDARD_DEVIATION 14.2 • n=42 Participants
|
47.1 years
STANDARD_DEVIATION 12.8 • n=31 Participants
|
44.4 years
STANDARD_DEVIATION 14.4 • n=41 Participants
|
43.3 years
STANDARD_DEVIATION 14.4 • n=44 Participants
|
46.0 years
STANDARD_DEVIATION 14.0 • n=312 Participants
|
|
Sex: Female, Male
Female
|
27 Participants
n=40 Participants • Information on sex was missing for 8 participants across treatment groups.
|
32 Participants
n=41 Participants • Information on sex was missing for 8 participants across treatment groups.
|
31 Participants
n=35 Participants • Information on sex was missing for 8 participants across treatment groups.
|
27 Participants
n=33 Participants • Information on sex was missing for 8 participants across treatment groups.
|
32 Participants
n=41 Participants • Information on sex was missing for 8 participants across treatment groups.
|
25 Participants
n=30 Participants • Information on sex was missing for 8 participants across treatment groups.
|
31 Participants
n=41 Participants • Information on sex was missing for 8 participants across treatment groups.
|
34 Participants
n=43 Participants • Information on sex was missing for 8 participants across treatment groups.
|
239 Participants
n=304 Participants • Information on sex was missing for 8 participants across treatment groups.
|
|
Sex: Female, Male
Male
|
13 Participants
n=40 Participants • Information on sex was missing for 8 participants across treatment groups.
|
9 Participants
n=41 Participants • Information on sex was missing for 8 participants across treatment groups.
|
4 Participants
n=35 Participants • Information on sex was missing for 8 participants across treatment groups.
|
6 Participants
n=33 Participants • Information on sex was missing for 8 participants across treatment groups.
|
9 Participants
n=41 Participants • Information on sex was missing for 8 participants across treatment groups.
|
5 Participants
n=30 Participants • Information on sex was missing for 8 participants across treatment groups.
|
10 Participants
n=41 Participants • Information on sex was missing for 8 participants across treatment groups.
|
9 Participants
n=43 Participants • Information on sex was missing for 8 participants across treatment groups.
|
65 Participants
n=304 Participants • Information on sex was missing for 8 participants across treatment groups.
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
4 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
3 Participants
n=35 Participants
|
1 Participants
n=35 Participants
|
5 Participants
n=42 Participants
|
3 Participants
n=31 Participants
|
6 Participants
n=41 Participants
|
5 Participants
n=44 Participants
|
31 Participants
n=312 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
36 Participants
n=42 Participants
|
37 Participants
n=42 Participants
|
32 Participants
n=35 Participants
|
32 Participants
n=35 Participants
|
36 Participants
n=42 Participants
|
27 Participants
n=31 Participants
|
34 Participants
n=41 Participants
|
37 Participants
n=44 Participants
|
271 Participants
n=312 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=35 Participants
|
2 Participants
n=35 Participants
|
1 Participants
n=42 Participants
|
1 Participants
n=31 Participants
|
1 Participants
n=41 Participants
|
2 Participants
n=44 Participants
|
10 Participants
n=312 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
0 Participants
n=35 Participants
|
2 Participants
n=35 Participants
|
1 Participants
n=42 Participants
|
3 Participants
n=31 Participants
|
3 Participants
n=41 Participants
|
3 Participants
n=44 Participants
|
17 Participants
n=312 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=35 Participants
|
1 Participants
n=42 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=41 Participants
|
1 Participants
n=44 Participants
|
3 Participants
n=312 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=35 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=41 Participants
|
0 Participants
n=44 Participants
|
0 Participants
n=312 Participants
|
|
Race (NIH/OMB)
Black or African American
|
3 Participants
n=42 Participants
|
3 Participants
n=42 Participants
|
1 Participants
n=35 Participants
|
0 Participants
n=35 Participants
|
5 Participants
n=42 Participants
|
5 Participants
n=31 Participants
|
5 Participants
n=41 Participants
|
2 Participants
n=44 Participants
|
24 Participants
n=312 Participants
|
|
Race (NIH/OMB)
White
|
32 Participants
n=42 Participants
|
32 Participants
n=42 Participants
|
32 Participants
n=35 Participants
|
31 Participants
n=35 Participants
|
28 Participants
n=42 Participants
|
20 Participants
n=31 Participants
|
28 Participants
n=41 Participants
|
34 Participants
n=44 Participants
|
237 Participants
n=312 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
1 Participants
n=35 Participants
|
0 Participants
n=35 Participants
|
2 Participants
n=42 Participants
|
2 Participants
n=31 Participants
|
3 Participants
n=41 Participants
|
1 Participants
n=44 Participants
|
12 Participants
n=312 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
4 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
1 Participants
n=35 Participants
|
2 Participants
n=35 Participants
|
5 Participants
n=42 Participants
|
1 Participants
n=31 Participants
|
2 Participants
n=41 Participants
|
3 Participants
n=44 Participants
|
19 Participants
n=312 Participants
|
|
Region of Enrollment
United States
|
42 participants
n=42 Participants
|
42 participants
n=42 Participants
|
35 participants
n=35 Participants
|
35 participants
n=35 Participants
|
42 participants
n=42 Participants
|
31 participants
n=31 Participants
|
41 participants
n=41 Participants
|
44 participants
n=44 Participants
|
312 participants
n=312 Participants
|
PRIMARY outcome
Timeframe: Baseline to Post-Intervention Survey (approximately 15-30 minutes)Investigators will measure this with the question "How likely are you to get an approved COVID-19 vaccine?" and "If you have received 1 dose of the Janssen vaccine or 2 doses of the Moderna or Pfizer vaccine, how likely are you to get an approved booster shot?" We will compare intention to receive a COVID-19 vaccine or booster among those receiving the interventions compared to those not receiving the intervention
Outcome measures
| Measure |
Condition 1
n=42 Participants
Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
|
Condition 2
n=42 Participants
Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 3
n=35 Participants
Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
|
Condition 4
n=35 Participants
Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 5
n=42 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 6
n=31 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an attention control educational message.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
|
Condition 7
n=41 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
|
Condition 8
n=44 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants Who Plan to Receive a COVID-19 Vaccine Post-intervention
|
19 Participants
|
24 Participants
|
19 Participants
|
21 Participants
|
24 Participants
|
19 Participants
|
23 Participants
|
16 Participants
|
SECONDARY outcome
Timeframe: Baseline to Month 2Population: Analysis includes participants who completed the 60-day follow-up survey (n=47)
The secondary outcome will be vaccine uptake, including self-report of receiving an initial dose of any approved vaccine, two doses of Pfizer or Moderna vaccines, or a booster of any approved vaccine.
Outcome measures
| Measure |
Condition 1
n=7 Participants
Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
|
Condition 2
n=5 Participants
Participants will not receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 3
n=4 Participants
Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
|
Condition 4
n=5 Participants
Patients will not receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 5
n=9 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an educational message about COVID-19 vaccines.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
Condition 6
n=3 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, motivational interviewing about serology SARS-CoV-2 antibody results with vaccination discussion, and an attention control educational message.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Motivational Interviewing: Participants will be randomized to receive either motivational interviewing when receiving SARS-CoV-2 antibody test results or standard interpretation of antibody results.
|
Condition 7
n=10 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an attention control educational message.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
|
Condition 8
n=4 Participants
Patients will receive a text message notifying participants about COVID-19 vaccine availability, standard interpretation of serology SARS-CoV-2 antibody results with COVID-19 vaccination discussion, and an educational message about COVID-19 vaccines.
Text Message: Participants will be randomized to receive or not receive a text message encouraging COVID-19 vaccine uptake.
Electronic Educational Message with Tailored Questions/Prompts: Participants will be randomized to receive either an electronic educational message tailored to their COVID-19 vaccine concerns and vaccine status or an attention control message about overall healthy choices.
|
|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants Who Self-report COVID-19 Vaccine Uptake
|
2 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
Adverse Events
Condition 1
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Condition 2
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Condition 3
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Condition 4
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Condition 5
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Condition 6
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Condition 7
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Condition 8
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Amanda Janitz
University of Oklahoma Health Sciences
Phone: 405-271-2229
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place